1
|
Feng V, Lanctot K, Herrmann N, Kiss A, Fischer CE, Flint AJ, Mah L, Mulsant BH, Pollock BG, Rajji TK, Tumati S, Verhoeff NP, Graff-Guerrero A, Gallagher D. Lipopolysaccharide, Immune Biomarkers and Cerebral Amyloid-Beta Deposition in Older Adults With Mild Cognitive Impairment & Major Depressive Disorder. Am J Geriatr Psychiatry 2023; 31:786-795. [PMID: 37211499 DOI: 10.1016/j.jagp.2023.04.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 04/21/2023] [Accepted: 04/24/2023] [Indexed: 05/23/2023]
Abstract
OBJECTIVE Inflammatory activation and increased immune response to lipopolysaccharide occur in both depression and cognitive decline and may link these two conditions. We investigated whether lipopolysaccharide (LPS), LPS binding protein (LBP) and peripheral biomarkers of immune response were associated with increased cerebral deposition of amyloid-beta (Abeta) in older adults with mild cognitive impairment (MCI) and remitted major depressive disorder (rMDD). DESIGN Cross-sectional analysis. SETTING Five academic health centers in Toronto. PARTICIPANTS Older adults with MCI with/without rMDD. MEASUREMENTS We investigated the associations among serum LPS, LBP, biomarkers of inflammatory activation - Interleukin-6 (IL-6), C-reactive protein (CRP), monocyte chemoattractant protein-1 (MCP-1), and cerebral Abeta deposition quantified by positron emission tomography. RESULTS Among 133 study participants (82 with MCI and 51 with MCI+rMDD) there was no association between LPS (beta - 0.17, p = 0.8) or LBP (beta - 0.11, p = 0.12) and global deposition of Abeta following adjustment for age, gender, and APOE genotype in multivariable regression analyses. LBP was positively correlated with CRP (r = 0.5, p <0.001) and IL-6 (r = 0.2, p = 0.02) but no inflammatory biomarker was associated with Abeta deposition; rMDD was not associated with deposition of Abeta (beta -0.09, p = 0.22). CONCLUSION In this cross-sectional analysis, we did not find an association among LPS/LBP, immune biomarkers or rMDD and global deposition of Abeta. Future analyses should assess the longitudinal relationships between peripheral and central biomarkers of immune activation, depression and cerebral Abeta deposition.
Collapse
Affiliation(s)
- Vivian Feng
- Neuropsychopharmacology Research Group (VF, KL, NH, AK, ST, DG), Sunnybrook Research Institute, Toronto, Canada
| | - Krista Lanctot
- Neuropsychopharmacology Research Group (VF, KL, NH, AK, ST, DG), Sunnybrook Research Institute, Toronto, Canada; Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
| | - Nathan Herrmann
- Neuropsychopharmacology Research Group (VF, KL, NH, AK, ST, DG), Sunnybrook Research Institute, Toronto, Canada; Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
| | - Alex Kiss
- Neuropsychopharmacology Research Group (VF, KL, NH, AK, ST, DG), Sunnybrook Research Institute, Toronto, Canada; Department of Health Policy, Management and Evaluation (AK), University of Toronto, Toronto, Canada
| | - Corinne E Fischer
- Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Keenan Research Centre for Biomedical Science (CEF), St. Michael's Hospital, Toronto, Canada
| | - Alastair J Flint
- Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Centre for Mental Health (AJF), University Health Network and University of Toronto, Toronto, Canada
| | - Linda Mah
- Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Department of Psychiatry (LM, NPV), Baycrest Health Sciences Centre, Toronto, Canada; Rotman Research Institute (LM), Baycrest Health Sciences Centre, Toronto, Canada
| | - Benoit H Mulsant
- Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Adult Neurodevelopment and Geriatric Psychiatry Division (BHM, BGP, TKR, AG-G), Centre for Addiction and Mental Health, Toronto, Canada; Toronto Dementia Research Alliance (BMH, BGP, TKR, NPV), University of Toronto, Toronto, Canada
| | - Bruce G Pollock
- Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Adult Neurodevelopment and Geriatric Psychiatry Division (BHM, BGP, TKR, AG-G), Centre for Addiction and Mental Health, Toronto, Canada; Toronto Dementia Research Alliance (BMH, BGP, TKR, NPV), University of Toronto, Toronto, Canada
| | - Tarek K Rajji
- Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Adult Neurodevelopment and Geriatric Psychiatry Division (BHM, BGP, TKR, AG-G), Centre for Addiction and Mental Health, Toronto, Canada; Toronto Dementia Research Alliance (BMH, BGP, TKR, NPV), University of Toronto, Toronto, Canada
| | - Shankar Tumati
- Neuropsychopharmacology Research Group (VF, KL, NH, AK, ST, DG), Sunnybrook Research Institute, Toronto, Canada
| | - Nicolaas Paul Verhoeff
- Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Department of Psychiatry (LM, NPV), Baycrest Health Sciences Centre, Toronto, Canada; Toronto Dementia Research Alliance (BMH, BGP, TKR, NPV), University of Toronto, Toronto, Canada
| | - Ariel Graff-Guerrero
- Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Adult Neurodevelopment and Geriatric Psychiatry Division (BHM, BGP, TKR, AG-G), Centre for Addiction and Mental Health, Toronto, Canada
| | - Damien Gallagher
- Neuropsychopharmacology Research Group (VF, KL, NH, AK, ST, DG), Sunnybrook Research Institute, Toronto, Canada; Department of Psychiatry (KL, NH, CEF, AJF, LM, BHM, BGP, TKR, NPV, AG-G, DG), Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
| |
Collapse
|
2
|
Shah-Basak PP, Kielar A, Deschamps T, Verhoeff NP, Jokel R, Meltzer J. Spontaneous oscillatory markers of cognitive status in two forms of dementia. Hum Brain Mapp 2018; 40:1594-1607. [PMID: 30421472 DOI: 10.1002/hbm.24470] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Revised: 10/09/2018] [Accepted: 11/01/2018] [Indexed: 01/23/2023] Open
Abstract
Abnormal oscillatory brain activity in dementia may indicate incipient neuronal/synaptic dysfunction, rather than frank structural atrophy. Leveraging a potential link between the degree of abnormal oscillatory activity and cognitive symptom severity, one could localize brain regions in a diseased but pre-atrophic state, which may be more amenable to interventions. In the current study, we evaluated the relationships among cognitive deficits, regional volumetric changes, and resting-state magnetoencephalography abnormalities in patients with mild cognitive impairment (MCI; N = 10; age: 75.9 ± 7.3) or primary progressive aphasia (PPA; N = 12; 69.7 ± 8.0), and compared them to normal aging [young (N = 18; 24.6 ± 3.5), older controls (N = 24; 67.2 ± 9.7]. Whole-brain source-level resting-state estimates of relative oscillatory power in the delta (1-4 Hz), theta (4-7 Hz), alpha (8-12 Hz), and beta (15-30 Hz) bands were combined with gray matter volumes and cognitive scores to examine between-group differences and brain-behavior correlations. Language and executive function (EF) abilities were impaired in patients with PPA, while episodic memory was impaired in MCI. Widespread oscillatory speeding and volumetric shrinkage was associated with normal aging, whereas the trajectory in PPA indicated widespread oscillatory slowing with additional volumetric reductions. Increases in delta and decreases in alpha power uniquely predicted group membership to PPA. Beyond volumetric reductions, more delta predicted poorer memory. In patients with MCI, no consistent group difference among oscillatory measures was found. The contributions of delta/alpha power on memory abilities were larger than volumetric differences. Spontaneous oscillatory abnormalities in association with cognitive symptom severity can serve as a marker of neuronal dysfunction in dementia, providing targets for promising treatments.
Collapse
Affiliation(s)
- Priyanka P Shah-Basak
- Rotman Research Institute, Baycrest Health Sciences Centre, Toronto, Ontario, Canada.,Canadian Partnership for Stroke Recovery, Ottawa, Ontario, Canada
| | - Aneta Kielar
- Rotman Research Institute, Baycrest Health Sciences Centre, Toronto, Ontario, Canada.,Canadian Partnership for Stroke Recovery, Ottawa, Ontario, Canada.,Department of Speech, Language, and Hearing Sciences, University of Arizona, Tucson, Arizona
| | - Tiffany Deschamps
- Rotman Research Institute, Baycrest Health Sciences Centre, Toronto, Ontario, Canada
| | - Nicolaas Paul Verhoeff
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.,Department of Psychiatry, Baycrest Health Sciences, North York, Ontario, Canada
| | - Regina Jokel
- Rotman Research Institute, Baycrest Health Sciences Centre, Toronto, Ontario, Canada.,Department of Psychiatry, Baycrest Health Sciences, North York, Ontario, Canada.,Department of Speech-Language Pathology, University of Toronto, Toronto, Ontario, Canada
| | - Jed Meltzer
- Rotman Research Institute, Baycrest Health Sciences Centre, Toronto, Ontario, Canada.,Canadian Partnership for Stroke Recovery, Ottawa, Ontario, Canada.,Department of Speech-Language Pathology, University of Toronto, Toronto, Ontario, Canada.,Department of Psychology, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
3
|
Verhoeff NP, Kapur S, Hussey D, Lee M, Christensen B, Papatheodorou G, Zipursky RB. A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 2001; 25:213-23. [PMID: 11425505 DOI: 10.1016/s0893-133x(01)00231-7] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The effect of endogenous dopamine (DA) on measurement of neostriatal DA D(2) receptor binding potential (D(2)RBP) in vivo was evaluated with positron emission tomography (PET) and the radiotracer [11C]raclopride by comparing the D(2)RBP before and after acute DA depletion. DA depletion was achieved by per-oral administration of 4.5 g alpha-methyl-para-tyrosine (AMPT) given in 25 h. Six healthy subjects completed the protocol. The AMPT treatment increased D(2)RBP significantly from 3.11 +/- 0.25 to 3.68 +/- 0.23 and decreased plasma levels of the DA metabolite homovanillic acid by 71 +/- 11% and levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenethyleneglycol by 53 +/- 7%. Increase in D(2)RBP correlated with decrease in attentiveness and with increase in errors of commission from Conners' Continuous Performance Test. On AMPT, a significant decrease in subjective happiness scores was observed. The results imply that a noninvasive [11C]raclopride PET protocol coupled with relatively brief administration of a rather low total dose of AMPT resulted in measurable acute DA depletion that might provide estimates of synaptic neostriatal DA concentration.
Collapse
Affiliation(s)
- N P Verhoeff
- PET Centre and Schizophrenia and Continuing Care Division, Clarke Site, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | | | | | |
Collapse
|
4
|
Tauscher J, Verhoeff NP, Christensen BK, Hussey D, Meyer JH, Kecojevic A, Javanmard M, Kasper S, Kapur S. Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. Neuropsychopharmacology 2001; 24:522-30. [PMID: 11282252 DOI: 10.1016/s0893-133x(00)00227-x] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Positron emission tomography (PET) and [11C]WAY-100635 were used to examine the effect of age on serotonin-1A (5-HT1A) receptor binding potential (BP) in 19 healthy subjects. Regions of interest (ROI) were drawn on the co-registered magnetic resonance imaging (MRI) in orbitofrontal (OFC), dorsolateral prefrontal (DLPFC), anterior cingulate (ACC), lateral (LTC), and mediotemporal (MTC), parietal, occipital and cerebellar cortex, and the raphe nuclei. BP values were calculated using a simplified reference tissue method. In addition, a voxelwise analysis was performed using SPM99. Voxelwise analysis revealed a significant global decrease of 5-HT(1A) BP with age (set level <.001). ROI analysis revealed significant age-related 5-HT(1A) BP decreases in DLPFC (r = -0.56), ACC (r = -0.44), OFC (r = -0.42), LTC (r = -0.40), parietal (r = -0.65), and occipital cortex (r = -0.43), but not in MTC or raphe nuclei. Overall, cortical 5-HT(1A) BP declined by approximately 10% per decade, except for the MTC, where we did not find a significant age effect. Hence, careful age matching may be recommended for future studies using PET and [11C]WAY-100635 to examine 5-HT1A receptors.
Collapse
Affiliation(s)
- J Tauscher
- PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Verhoeff NP, Meyer JH, Kecojevic A, Hussey D, Lewis R, Tauscher J, Zipursky RB, Kapur S. A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Psychiatry Res 2000; 99:123-35. [PMID: 11068194 DOI: 10.1016/s0165-1781(00)00198-0] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Several postmortem studies have reported regionally localized decreases in serotonin(2A) receptors (5-HT(2A)R) in schizophrenia. This was not confirmed by two recent [18F]setoperone positron emission tomography (PET) studies. In these two studies relatively large regions of interest (ROIs) were used; hence, 5-HT(2A)R changes may have been missed in some brain areas. Therefore, data from one study were analyzed on a voxel-by-voxel basis using Statistical Parametric Mapping (SPM). We also used this method to examine the relationship between 5-HT(2A)R binding potential (BP) and five PANSS-derived factors: negative, positive, activation, dysphoric and autistic preoccupation. Thirteen schizophrenic patients (10 antipsychotic-naïve, 3 antipsychotic-free; 11 M, 2 F; age 31+/-7 years) and 35 age-matched control subjects (15 M, 20 F; age 30+/-7 years) were scanned. The 5-HT(2A)R BP was determined for each voxel using the pseudoequilibrium ratio method on PET data obtained between 65 and 90 min after [18F]setoperone bolus injection. The resulting parametric 5-HT(2A)R BP images were spatially normalized using a ligand specific template. Analyses of covariance were done using SPM99 with age as covariate. In tests for the effect of schizophrenia and for partial correlations between 5-HT(2A)R BP and the five factors, corrected P values <0.05 at cluster or voxel level were considered significant. No significant differences were detected between patients and control subjects, and no significant correlations were observed between 5-HT(2A)R BP and any of the five factors. Thus, in agreement with the previous ROI studies, voxel-by-voxel analysis confirmed the lack of substantial 5-HT(2A)R BP differences between schizophrenic patients and control subjects.
Collapse
Affiliation(s)
- N P Verhoeff
- PET Centre and Schizophrenia and Continuing Care Division, Clarke Site, Centre for Addiction and Mental Health, University of Toronto, ON, M5T 1R8, Toronto, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Varrone A, Fujita M, Verhoeff NP, Zoghbi SS, Baldwin RM, Rajeevan N, Charney DS, Seibyl JP, Innis RB. Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans. J Nucl Med 2000; 41:1343-51. [PMID: 10945525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
UNLABELLED This study evaluated the test-retest reproducibility of D2 receptor quantification in the thalamus and temporal cortex using [123I]epidepride SPECT. METHODS Ten healthy volunteers (4 men, 6 women; age range, 19-46 y) underwent 2 SPECT studies (interval, 2-26 d) using a bolus-plus-constant-infusion paradigm (bolus-to-infusion ratio = 6 h; infusion time = 9 h). Plasma clearance (in liters per hour) and free fraction (f1) of the parent tracer were measured. Radioactivity (in becquerels per gram) in the thalamus, temporal cortex, and cerebellum were normalized to the infusion rate (in becquerels per hour). Normalized striatal radioactivity was also measured to assess reproducibility in regions with a high density of receptors and better counting statistics. The outcome measures obtained were V3 (receptor density [Bmax]/equilibrium dissociation constant [KD]), V3' (f1 x Bmax/KD), and RT (specific-to-nondisplaceable tissue ratio). RESULTS Test-retest variability and reliability (intraclass correlation coefficient) were 10.8% and 0.88, respectively, for plasma clearance and 15.3% and 0.77, respectively, for f1. The test-retest variability of brain-specific (target minus nondisplaceable) radioactivity was higher in the thalamus and temporal cortex than in the striatum, although reliability was comparable. Among the outcome measures, V3' showed better test-retest variability and reliability in the thalamus (13.3% and 0.75, respectively) and temporal cortex (13.4% and 0.86, respectively). CONCLUSION Brain radioactivity was the main source of variability for quantification of extrastriatal D2 receptors with [123I]epidepride. The reproducibility of outcome measures in extrastriatal regions was good. However, because receptor density was lower in extrastriatal regions than in the striatum, the counting statistics in these regions were low and reproducibility was affected by the higher test-retest variability of brain-specific radioactivity. Compared with V3 and V3', RT showed less test-retest variability in the thalamus and temporal cortex but lower reliability. Moreover, measurement of RT may be affected by the presence of potential lipophilic metabolites entering the brain.
Collapse
Affiliation(s)
- A Varrone
- Department of Diagnostic Radiology, Yale University School of Medicine, and VA Connecticut, West Haven, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Fujita M, Verhoeff NP, Varrone A, Zoghbi SS, Baldwin RM, Jatlow PA, Anderson GM, Seibyl JP, Innis RB. Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol 2000; 387:179-88. [PMID: 10650158 DOI: 10.1016/s0014-2999(99)00817-1] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The effect of endogenous dopamine on in vivo measurement of dopamine D(2) receptors in extrastriatal regions (thalamus and temporal cortex) was evaluated with single photon emission computed tomography and the high affinity ligand [123I]epidepride by comparing the binding potential before and after acute dopamine depletion. Dopamine depletion was achieved by per-oral administration of 5.5 g/70 kg body weight alpha-methyl-para-tyrosine given in 37 h. The alpha-methyl-para-tyrosine treatment increased the binding potential significantly in the temporal cortex (13+/-15%, P=0.036) but not in the thalamus (2+/-9%). The increase of the binding potential in the temporal cortex correlated strongly with the increase of dysphoric mood evaluated by the Positive and Negative Symptom Scale (PANSS) (rho=0.88, P=0.004). These results imply that [123I]epidepride, coupled with acute dopamine depletion might provide estimates of synaptic dopamine concentration.
Collapse
Affiliation(s)
- M Fujita
- Department of Psychiatry, Yale University, VA Connecticut, West Haven, CT 06516, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Fujita M, Seibyl JP, Verhoeff NP, Ichise M, Baldwin RM, Zoghbi SS, Burger C, Staley JK, Rajeevan N, Charney DS, Innis RB. Kinetic and equilibrium analyses of [(123)I]epidepride binding to striatal and extrastriatal dopamine D(2) receptors. Synapse 1999; 34:290-304. [PMID: 10529723 DOI: 10.1002/(sici)1098-2396(19991215)34:4<290::aid-syn5>3.0.co;2-b] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Quantitative SPECT measures of dopamine D(2) like receptors with [(123)I]epidepride is complicated by its high affinity and lipophilic metabolites. The purpose of this study was to use both parent (P) and lipophilic metabolites (M) as input functions in a kinetic paradigm and in comparison to the results of equilibrium studies. Kinetic studies on eleven healthy human subjects, ages 32+/- 10 were performed following i.v. injection of approximately 370 MBq of [(123)I]epidepride. Images were acquired for 13.5+/-1.0 hours. Equilibrium studies were done on seven of eleven subjects with a bolus injection of approximately 140 MBq, bolus/infusion ratio of 10 hours, and infusion for 30-32 hours. High (striatum) and low (temporal cortex) density regions were studied. Two (P and M) and one (P) input function models were applied in the kinetic studies. In receptor-rich regions, the distribution volumes in nondisplaceable compartments were fixed to those in cerebellum. In addition, in the two input function model, K(1)(P)/K(1)(M) was fixed to the values in the cerebellum. The one input function model provided V'(3) values (=f(1)*B'(max)/K(D)) which were consistent with those obtained in equilibrium studies in both receptor-rich regions, while the two input function model provided consistent values only in striatum. Poor identifiability of the rate constants of metabolites seemed to be the source of errors in the two input function model. These results suggest that correct V'(3) values can be obtained with the one input function model both in high- and low-density regions.
Collapse
Affiliation(s)
- M Fujita
- Department of Psychiatry, Diagnostic Radiology, and Pharmacology, Yale University and VA Connecticut, West Haven, Connecticut 06516, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
This article will review the capabilities and accomplishments of radiotracer imaging with single photon emission computed tomography (SPECT) and positron emission tomography (PET) to measure pre-, post-, and "intra-synaptic" aspects of dopaminergic (DAergic) neurotransmission. The presynaptic site can be labeled with probes for the dopamine transporter (DAT) or the synthetic enzyme aromatic L-amino acid decarboxylase ("dopa decarboxylase"). The postsynaptic sites can be labeled with probes for either the dopamine D1 receptor (D1R) or the dopamine D2 receptor (D2R). The "synaptic" measurements are made indirectly by measurements of the interaction/displacement of receptor tracers by endogenous dopamine (DA). Agents are used which either release (e.g., amphetamine) or deplete (e.g., alpha-methyl-paratyrosine (AMPT), an inhibitor of tyrosine hydroxylase) tissue stores of DA. The application of these paradigms will be reviewed with special emphasis to neuropsychiatric diseases such as schizophrenia and idiopathic Parkinson's disease (IPD).
Collapse
Affiliation(s)
- N P Verhoeff
- University of Toronto, Centre for Addiction and Mental Health, Ontario, Canada.
| |
Collapse
|
10
|
Ichise M, Fujita M, Seibyl JP, Verhoeff NP, Baldwin RM, Zoghbi SS, Rajeevan N, Charney DS, Innis RB. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. J Nucl Med 1999; 40:1902-12. [PMID: 10565788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
UNLABELLED The purpose of this study was to extend the graphical analysis of reversible tracer binding to account for labeled lipophilic metabolites (metabolites) in quantifying [123I]epidepride binding to striatal and extrastriatal D2 receptors and, additionally, to evaluate the feasibility of simplified analysis to measure the specific volume of distribution (V3') using single-sample blood data because the tissue ratio (RT) may be a less reliable measure of D2 binding in the presence of metabolites. METHODS Multilinear regression analysis (MLRA) and graphical analysis (GA) using plasma parent (P) plus metabolite (M) activities as input and time activities of receptor-free (RF, cerebellum) and receptor-containing regions (RR, striatum and temporal cortex) derived V3' = (alpha(RR)(P) - alpha(RF)(P)), V3' = (1 + delta) (alpha(RR) - alpha(RF)) and RT = V3'/(V2P' + deltaV2M'), where alpha is a regression coefficient, delta is the equilibrium area ratio of M and P, and (V2P'/V2M') are the corresponding nondisplaceable distribution volumes. V3' by simplified analysis (SA) was calculated from RT determined without blood data and (V2P' + deltaV2M') with single-blood sample data. The accuracy of these three V3' values was assessed relative to the metabolite-accounted kinetic analysis (KA) for [123I]epidepride SPECT studies of 11 healthy volunteers, in which each participant had 27 scans and 30 plasma samples drawn during the 14 h after injection. RESULTS All three V3' values (mL/g) significantly correlated with those by KA (r > or = 0.90) (striatum/temporal cortex: MLRA, 77.8 +/- 36.6/2.35 +/- 1.16; GA, 98.8 +/- 34.2/4.61 +/- 1.77; SA, 83.9 +/- 24.8/4.26 +/- 1.74; KA, 107.6 +/- 34.4/5.61 +/- 1.84). However, the correlation between RT and V3' was only moderate (r < or = 0.65) because of significant intersubject variability (23%) in (V2P' + deltaV2M'). CONCLUSION The graphical analysis can be extended to account for metabolites in measuring D2 binding with [123I]epidepride SPECT for both high and low D2 density regions. Additionally, simplified V3' measurements with single blood sampling are feasible and may be a practical alternative to the tissue ratio RT because RT suffers as a measure of D2 binding from significant intersubject variability in the metabolite-contributed distribution volume of the nondisplaceable compartment.
Collapse
Affiliation(s)
- M Ichise
- Department of Nuclear Medicine, Mount Sinai Hospital, and University of Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Verhoeff NP, Soares JC, D'Souza CD, Gil R, Degen K, Abi-Dargham A, Zoghbi SS, Fujita M, Rajeevan N, Seibyl JP, Krystal JH, van Dyck CH, Charney DS, Innis RB. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res 1999; 91:163-73. [PMID: 10641580 DOI: 10.1016/s0925-4927(99)00027-x] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Deficient inhibitory neurotransmission of gamma-aminobutyric acid (GABA) has been implicated in the pathophysiology of schizophrenia based on postmortem studies. However, in vivo studies have shown predominantly negative or conflicting results. The goal of this study was to better characterize possible changes of the regional GABA(A)-benzodiazepine receptor distribution volume (BZR V3-p) in schizophrenia in vivo, using a larger sample size than previous studies. Single photon emission computed tomography (SPECT) with [123I]iomazenil was used with a constant infusion paradigm to measure the BZR V3-p under sustained radiotracer equilibrium conditions. Twenty-five patients with schizophrenia and 24 matched healthy control subjects were studied. Positive and Negative Syndrome Scale (PANSS) ratings were done in all subjects. Statistical parametric mapping (SPM) 96 was used to compare patients and control subjects as well as to study the relationship between SPECT results and composite PANSS scores based on two factorial models: the pentagonal model (positive, negative, dysphoric mood, activation, and autistic preoccupation factors) and the taxometric model (disorganized dimension). On the basis of 'absolute' values of V3-p with no normalization for total brain uptake, the schizophrenic patients showed no significant differences in BZR levels compared to the healthy control subjects. With a global normalization procedure, which is more sensitive to relative regional differences in activity, BZR V3-p was significantly decreased in the patients in the left precentral gyrus (BA 6). The relative BZR V3-p showed a significant positive correlation with duration of illness in the superior occipital gyri (BA 19). No significant correlations were observed between either absolute or relative BZR V3-p and either age or any of the composite PANSS scores based on any of the two factorial models in either patients or control subjects. No significant differences were observed between cigarette smoking vs. non-smoking patients, nor between the patients on atypical antipsychotics vs. on typical antipsychotics vs. not on any antipsychotics. In general, no significant differences in BZR V3-p were observed between patients and control subjects, except for a decrease in relative BZR V3-p in the left precentral gyrus. Grey matter atrophy is unlikely to be the cause for this decrease. However, we could not exclude that possibility. The positive correlation with duration of illness might reflect the relative preservation of neurons expressing BZR in the superior occipital gyri as compared to other cortical brain regions in schizophrenia.
Collapse
Affiliation(s)
- N P Verhoeff
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Verhoeff NP, Petroff OA, Hyder F, Zoghbi SS, Fujita M, Rajeevan N, Rothman DL, Seibyl JP, Mattson RH, Innis RB. Effects of vigabatrin on the GABAergic system as determined by [123I]iomazenil SPECT and GABA MRS. Epilepsia 1999; 40:1433-8. [PMID: 10528940 DOI: 10.1111/j.1528-1157.1999.tb02016.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
PURPOSE To evaluate effects of vigabatrin (VGB) by using [123I]iomazenil single-photon emission computed tomography (SPECT) to estimate central gamma-aminobutyric acid (GABA(A))/benzodiazepine receptors (BZRs), and magnetic resonance spectroscopy (MRS) to assess tissue GABA levels. METHODS Six patients with partial seizures had both SPECT and MRS before and 25-84 days after starting VGB (3 g p.o., q.d.). SPECT was acquired by using the constant-infusion method and, after nonuniform attenuation correction, coregistered with T1-weighted MR Imaging (MRI) A volume of interest (VOI) of 3 x 2 x 2 cc over the occipital cortex, used for MRS acquisition, was positioned on both MRI and coregistered SPECT. Occipital activity was divided by either total plasma activity or plasma [123I]iomazenil concentration to estimate BZR distribution volume (V(T)-p and V'(T), respectively). Wilcoxon's test was used for VOI differences in GABA levels, BZR V(T)-p or V'(T). SPM96 (either no global normalization or proportional scaling) was used to compare BZR V(T)-p changes in the patients with and without VGB with test-retest data in eight healthy age-matched controls. RESULTS Occipital GABA levels were increased threefold (without VGB, 1.1+/-0.1 micromol/g; with VGB, 2.9+/-0.5 micromol/g; p = 0.027). BZR distribution volumes showed no change, when estimated by either V(T)-p (without VGB, 6.00+/-0.91 ml/g; with VGB, 5.86+/-0.44 ml/g; p = 0.92) or V(T) (without VGB, 41.1+/-11.2 ml/g; with VGB, 41.2+/-9.9 ml/g; p = 0.75). No significant changes were detected by SPM96. CONCLUSIONS A clinically effective dose of VGB caused a threefold increase in tissue GABA levels but was not associated with a substantial BZR downregulation.
Collapse
Affiliation(s)
- N P Verhoeff
- Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Fujita M, Woods SW, Verhoeff NP, Abi-Dargham A, Baldwin RM, Zoghbi SS, Soares JC, Jatlow PA, Krystal JH, Rajeevan N, Charney DS, Seibyl JP, Innis RB. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur J Pharmacol 1999; 368:161-72. [PMID: 10193652 DOI: 10.1016/s0014-2999(99)00013-8] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Changes of central type GABA(A)/benzodiazepine receptors during 24-day per-oral administration of alprazolam (2 mg/day) were measured with single photon emission computed tomography (SPECT) in nine healthy human subjects. Receptor densities were measured on days -4 (baseline), 3, 10, 17 and 24. Comparison of baseline and day 3 SPECT images was used to assess receptor occupancy; comparisons of the four scans on medication were used to assess alterations in receptor levels. Clinical effects were evaluated by subjective ratings of mood and the Hopkins verbal learning test. Alprazolam induced sedation associated with a 16% receptor occupancy. Unoccupied receptor levels decreased 10% from day 3 to day 10 but then normalized to baseline values by day 17. Clinical effects showed corresponding changes 1-2 weeks after the changes in the receptor. Thus, the decrease of benzodiazepine receptor densities may be one of the major mechanisms for tolerance development in humans.
Collapse
Affiliation(s)
- M Fujita
- Department of Psychiatry, Yale University School of Medicine, West Haven, CT 06516, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Verhoeff NP. Benzodiazepine receptor binding and schizophrenia. Am J Psychiatry 1997; 154:1480. [PMID: 9326849 DOI: 10.1176/ajp.154.10.1480a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
15
|
Bornebroek M, Verzijlbergen JF, Haan J, Van Scheyen EJ, Verhoeff NP, Pauwels EK, Roos RA. Potential for imaging cerebral amyloid deposits using 123I-labelled serum amyloid P component and SPET. Nucl Med Commun 1996; 17:929-33. [PMID: 8971863 DOI: 10.1097/00006231-199611000-00002] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The systemic and cerebral accumulation of 123I-labelled serum amyloid P component (123I-SAP) was studied in patients with hereditary cerebral amyloid angiopathy-Dutch type (HCHWA-D) to determine the usefulness of 123I-SAP imaging in cerebral amyloidosis. Whole-body and SPET scintigraphic imaging was performed in two patients with HCHWA-D and four controls after the intraveous injection of 123I-SAP. Venous 123I-SAP clearance was also determined. Accumulation of the tracer was observed in the cerebral cortex of both patients, whereas no accumulation was seen in the controls. Blood clearance of radioactivity was similar in the patients and controls, suggesting that the amount of uptake of 123I-SAP in the cerebral amyloid deposits is relatively small. We believe this to be the first demonstration of cerebral amyloid deposits in vivo. Our findings indicate that 123I-SAP scintigraphy has possibilities for the diagnosis of patients with cerebral amyloid diseases, in addition to its use in patients with systemic amyloid deposition.
Collapse
Affiliation(s)
- M Bornebroek
- Department of Neurology, Leiden University Hospital, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
16
|
van Royen EA, Verhoeff NP, Meylaerts SA, Miedema AR. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands. J Nucl Med 1996; 37:1449-51. [PMID: 8790190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
UNLABELLED Pituitary uptake of [111In-DTPA]-octreotide is highly variable, and no formal methods for quantification have been described. Conflicting results have therefore been published as to the presence of somatostatin receptors in nonsecreting adenoma of the pituitary gland. The aim of the present study was to define the most accurate method for the analysis of [111In-DTPA]-octreotide SPECT studies of the pituitary gland. METHODS We used a multidetector brain SPECT camera to measure pituitary uptake of [111In-DTPA]-octreotide in healthy volunteers and patients with and without pituitary adenoma. For quantification, two methods were compared, one involving a manually drawn ROI and one a fixed ROI, as to their reliability and discriminative power. The optimal time interval after injection was also studied in the volunteers. RESULTS Optimal images were obtained 24 hr after injection. Correction for background activity is not useful in view of the very low counts at that time which result in highly fluctuating ratios. Lower variability was observed in the fixed ROI method in which activity was expressed as counts corrected for dosage and body weight. CONCLUSION A fixed ROI method without background correction is the most reliable way to measure pituitary uptake of [111In-DTPA]-octreotide. This method allows for good separation of somatostatin-receptor-positive adenomas from normal pituitary glands.
Collapse
Affiliation(s)
- E A van Royen
- Department of Nuclear Medicine, University of Amsterdam, The Netherlands
| | | | | | | |
Collapse
|
17
|
Busatto GF, Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Kerwin RW. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1995; 117:55-61. [PMID: 7536945 DOI: 10.1007/bf02245098] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Risperidone and remoxipride are recently introduced atypical antipsychotics, with clinical efficacy comparable to that of classical antipsychotics but lower propensity to induce extrapyramidal side effects (EPS). It is unclear whether these properties relate to weak dopamine D2 receptor blockade in vivo, as has been suggested for the archetypal atypical antipsychotic clozapine. We have used 123I-IBZM single photon emission tomography (SPET) to characterize the patterns of striatal D2 receptor binding in vivo in DSMIII-R-diagnosed schizophrenic and schizo-affective patients treated with either risperidone (n = 6) or remoxipride (n = 4) but predominantly EPS free. These groups were compared to age- and BPRS- matched subjects from a previously reported D2 receptor binding database of patients treated with clozapine (n = 10) and classical antipsychotics (n = 10). Patients on risperidone and remoxipride had high levels of D2 receptor blockade, comparable to those of patients on classical antipsychotics, and significantly greater than those obtained with clozapine-treated patients (risperidone versus clozapine, P < 0.005; remoxipride versus clozapine, P < 0.025). These results suggest high levels of striatal D2 receptor occupancy in association with remoxipride and risperidone treatment and argue against modest D2 antagonism as the explanation for the low incidence of EPS associated with these drugs.
Collapse
Affiliation(s)
- G F Busatto
- Department of Psychological Medicine, Institute of Psychiatry, Denmark Hill, London, UK
| | | | | | | | | | | |
Collapse
|
18
|
Abstract
A large body of evidence suggests that abnormal dopaminergic activity is present in Gilles de la Tourette Syndrome (GTS). To investigate whether dopamine dysregulation involving the D2/D3 receptor occurs in GTS, we performed single slice dynamic single photon emission computed tomography (SPECT) with 123iodo-6-methoxybenzamide (123I-IBZM) in 15 GTS patients (eight unmedicated) and six healthy volunteers. After intravenous administration of 5 mCi (185 MBq) of 123I-IBZM, dynamic SPECT (5 minutes per slice) studies were performed at the level of the basal ganglia for 55 minutes. The mean activity per pixel in the basal ganglia was compared with the mean activity per pixel in the visual cortex. Unmediated GTS patients showed no differences from control subjects. However, GTS patients taking D2 blocking medications had significantly decreased 123I-IBZM binding compared with control subjects in both the right and left basal ganglia. Thus, D2/D3 receptor availability, as measured by 123I-IBZM SPECT, is not abnormal in GTS.
Collapse
Affiliation(s)
- M S George
- Department of Clinical Neurology, Institute of Neurology, London, England
| | | | | | | | | | | | | |
Collapse
|
19
|
Vermeulen RJ, Drukarch B, Verhoeff NP, Goosen C, Sahadat MC, Wolters EC, van Royen EA, Stoof JC. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys. Synapse 1994; 17:115-24. [PMID: 7916490 DOI: 10.1002/syn.890170207] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Almost no information is available concerning the link between clinical effects of dopamine D2 receptor agonists in the treatment of Parkinson's disease (PD) and the extent of D2 receptor occupancy in the brain. Therefore, we investigated the possible correlation between administration of behaviorally active doses of the selective D2 agonist LY 171555 and in vivo D2 receptor occupancy in the unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-lesioned rhesus monkey model of PD. Single photon emission computed tomography (SPECT) with the D2 receptor antagonist [123I]IBZM (iodobenzamide) as radioligand was used to estimate the receptor occupancy. The MPTP-lesioned monkeys consistently showed signs of unilateral parkinsonism. LY 171555 (0.01 or 0.3 mg/kg) significantly increased contralateral rotation (away from the lesion), being most effective at the lower dose. In the MPTP-lesioned monkeys [123I]IBZM activity in the left (lesioned) striatum was significantly higher as compared to that in the right striatum. Only upon administration of 0.3 mg/kg LY 171555 a significant amount of receptor occupancy by LY 171555, as measured with [123I]IBZM SPECT, at both lesioned and non-lesioned side, was detected. Using D2 receptor mediated inhibition of the evoked release of [3H]acetylcholine from rat striatal tissue as a functional model, we showed that the lack of effect with 0.01 mg/kg LY 171555 was not due to non-competitive interaction between LY 171555 and IBZM at the D2 receptor. We conclude that the D2 antagonist [123I]IBZM is not a suitable SPECT ligand to study the relationship between behavioral effects of the selective D2 agonist LY 171555 in unilaterally MPTP-lesioned monkeys and the D2 receptor occupancy in vivo in this animal model of PD.
Collapse
Affiliation(s)
- R J Vermeulen
- Department of Neurology, Graduate School Neuroscience Amsterdam, Vrije Universiteit, Rijswijk, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
Animal models suggest a relationship between disturbed striatal dopaminergic function and stereotyped behaviour. Several studies show increased stereotypy in schizophrenic patients compared to normal controls. We investigated the performance of 12 antipsychotic-drug-free schizophrenic patients, and 15 healthy control subjects on a neuropsychological measure of stereotypy--the two-choice guessing task--and correlated this with in vivo striatal dopamine D2 receptor binding, as measured by 123I-iodobenzamide single photon emission tomography. Patients and controls did not differ with respect to the measures of stereotypy derived from the task. However, there was a significant correlation between one of these measures (RR Information) and the degree of striatal D2 receptor binding asymmetry in the patient group only. In view of research connecting striatal and frontal lesions with stereotypy in animals and cognitive inflexibility in humans, these data could suggest a similar disturbance underlying the phenomenon in schizophrenia.
Collapse
Affiliation(s)
- B M Pedro
- Department of Psychology, Institute of Psychiatry, London
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
In order to study the nature of dopaminergic activity in epileptic psychoses we investigated striatal dopamine receptor binding in 14 patients with epilepsy. Seven of the patients were acutely psychotic when studied, having recently developed a periictal schizophreniform psychosis. The remaining patients were not psychotic. All patients were scanned using single photon emission tomography (SPET) with 123I-IBZM, a specific dopamine D2 receptor ligand. A region of interest analysis was performed. Comparison of mean basal ganglia to occipital cortex activity ratios in the two groups demonstrated significantly reduced specific binding of 123I-IBZM to striatal D2 receptors in the psychotic patients compared to those without psychosis.
Collapse
Affiliation(s)
- H A Ring
- Raymond Way Neuropsychiatry Research Group, Institute of Neurology, London, England
| | | | | | | | | | | |
Collapse
|
22
|
Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 1994; 164:16-26. [PMID: 8137105 DOI: 10.1192/bjp.164.1.16] [Citation(s) in RCA: 98] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
We used SPECT to examine striatal D2 receptor binding in 20 antipsychotic-free DSM-III-R schizophrenic patients and 20 age- and sex-matched normal controls. Dynamic single-slice SPECT, at a slice chosen to include the basal ganglia, began immediately following intravenous injection of 185 MBq of 123I-IBZM. A semiquantitative approach was used to generate indices of specific D2 receptor binding in the basal ganglia. There was no overall elevation of D2 receptor binding between patients and controls. A male sex-specific left lateralised asymmetry of striatal D2 receptor binding was found in the patient group. Age-dependent decline of striatal D2 receptors was confirmed in controls, but not in patients. These results suggest that alterations in striatal D2 receptor distribution and density do occur in schizophrenia, and possibly reflect wider disruptions in prefrontal-striatal-limbic circuits.
Collapse
Affiliation(s)
- L S Pilowsky
- Institute of Psychiatry, De Crespigny Park, London
| | | | | | | | | | | |
Collapse
|
23
|
Verhoeff NP, Kapucu O, Sokole-Busemann E, van Royen EA, Janssen AG. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. J Nucl Med 1993; 34:2076-84. [PMID: 8254390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Factors contributing to the quantification of the striatal dopamine D2 receptor binding potential in vivo using 123I-iodobenzamide (123I-IBZM) and SPECT were analyzed in phantom studies, healthy volunteers and in patients with the parkinsonian syndrome. A cylindrical brain phantom based on a stereotactic brain atlas was constructed with independently fillable compartments representing two striata (ST), cerebellum (CB) and background. Clinical 123I-IBZM SPECT studies were performed on 15 healthy volunteers and on 28 patients with parkinsonian syndrome. Interobserver variability of region of interest (ROI) selection and count ratios were estimated by two independent observers. ROIs for the striatum were either fixed, based on a stereotactic brain atlas, or drawn manually, based on 70% isocontour lines. Reference regions were either the cerebellum (isocontour ROIs) or the occipital cortex (occiptal cortex; fixed ROIs). The brain phantom measurements showed linearity with respect to radioactivity concentration, good reproducibility and good contrast recovery. The interobserver study showed that the striatum-to-occiptal cortex ratio with fixed ROIs for the striatum, as an estimate for striatal D2 receptor binding potential, resulted in a means of separating patients with normal receptor activity from those with decreased striatal dopamine D2 receptor activity.
Collapse
Affiliation(s)
- N P Verhoeff
- Department of Nuclear Medicine, Academic Medical Centre, Amsterdam, The Netherlands
| | | | | | | | | |
Collapse
|
24
|
Busatto GF, Pilowsky LS, Ell PJ, Costa DC, Verhoeff NP, Kerwin RW. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone. Br J Psychiatry 1993; 163:833-4. [PMID: 7508329 DOI: 10.1192/bjp.163.6.833] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
25
|
Verhoeff NP, Visser WH, Ferrari MD, Saxena PR, van Royen EA. Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Cephalalgia 1993; 13:325-9. [PMID: 8242725 DOI: 10.1046/j.1468-2982.1993.1305325.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal. Results were compared with 15 healthy controls. Striatum/cerebellum and striatum/occipital cortex ratios of count rate density were calculated as a semiquantitative measurement for striatal dopamine D2-receptor binding potential. No differences were found in striatal uptake of 123I-IBZM between healthy controls and the patients when on or off ergotamine. Preliminary evidence suggests that ergotamine may not occupy striatal dopamine D2-receptors to a large extent and thus may not cross the blood brain barrier in large quantities.
Collapse
Affiliation(s)
- N P Verhoeff
- Department of Nuclear Medicine, Academic Medical Centre, Amsterdam, The Netherlands
| | | | | | | | | |
Collapse
|
26
|
Verhoeff NP, Sokole EB, Stabin M, Hengst D, Kung HF, Van Royen EA, Janssen AG. Dosimetry of iodine-123 iodobenzamide in healthy volunteers. Eur J Nucl Med 1993; 20:747-52. [PMID: 8223767 DOI: 10.1007/bf00180903] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The distribution of the dopamine D2-receptor specific ligand iodine-123 (S)-(-)-2-hydroxy-3-iodo-6-methoxy-N[(1-ethyl-2- pyrrolidinyl)methyl]-benzamide (123I-IBZM) was investigated in human adults from whole-body scans, blood samples and urine collected up to 48 h after injection. Results from the present study performed in six healthy volunteers were combined with those of five volunteers from a previous study. Using the brain, liver, lungs and spleen as source organs, the MIRD method was applied to calculate the absorbed radiation dose of the radioligand in various organs. The thyroid (despite blockage), gallbladder wall, large intestinal walls and spleen received the highest absorbed doses. The average effective dose equivalent of 123I-IBZM for adults was estimated to be 0.034 mSv/MBq. The absorbed dose to the thyroid may be a limiting factor for 123I-IBZM studies in children.
Collapse
Affiliation(s)
- N P Verhoeff
- Department of Nuclear Medicine, Academic Medical Centre, Amsterdam, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
27
|
Verhoeff NP, Erbas B, Kapucu O, Busemann Sokole E, Blok H, Van Royen EA. Quantification of central benzodiazepine receptor binding potential in the brain with 123I-iomazenil SPECT: technical and interobserver variability. Nucl Med Commun 1993; 14:634-43. [PMID: 8396758 DOI: 10.1097/00006231-199308000-00003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Factors contributing to the quantification of the central benzodiazepine receptor binding potential in vivo using 123I-iomazenil and single photon emission computed tomography (SPECT) were analysed in phantom studies and in volunteers. SPECT was performed with the SME810 multidetector system. The Hoffman three-dimensional brain phantom was used to investigate linearity and reproducibility of SPECT results using different 123I activity concentrations. Dynamic and multislice SPECT scans were performed in nine healthy volunteers between 0 and 270 min after injection of 110 MBq 123I-iomazenil. Displacement studies were performed in three volunteers using 1 mg flumazenil administered intravenously (i.v.) at 250 min postinjection (p.i.). Regions of interest (ROIs) over the cerebral cortex and various subcortical nuclei were either fixed areas based on a stereotaxic brain atlas, or manually drawn, based on 60% isocontour lines. Interobserver variability of the ROI data and ratios derived from those data were estimated for two independent observers. The brain phantom measurements showed linearity with respect to 123I concentration and good reproducibility. The interobserver study showed a reasonable interobserver reliability for the large fixed ROIs. The displacement study showed about 50% displacement in all ROIs. Concentrations of 123I-iomazenil in the brain can be measured reliably with the SME810. Large fixed ROIs based on a stereotaxic atlas may be used reliably for quantification. The level of 4 cm above the cantomeatal line does not provide a useful reference region with a very low central benzodiazepine receptor binding potential.
Collapse
Affiliation(s)
- N P Verhoeff
- Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
28
|
Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol Med 1993; 23:791-797. [PMID: 7901865 DOI: 10.1017/s0033291700025575] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The hypothesis that poor response to antipsychotic medication is due to inadequate occupancy of central D2 receptors was tested in vivo. We assessed striatal D2 dopamine receptor availability for binding with the specific ligand 123I IBZM by single photon emission tomography (SPET) in two groups of DSM-III-R diagnosed schizophrenic patients on typical antipsychotic medication, and a group of healthy controls (N = 20). Patients were characterized by clinical ratings as antipsychotic responders (N = 10) or non-responders (N = 8). Dynamic single slice SPET, at a slice chosen to include the basal ganglia, began immediately following intravenous injection of 185 MBq 123I IBZM. Semiquantitative analysis generated indices of D2 receptor availability for binding. There was no difference in striatal D2 receptor availability between the patient groups, both showing a similar degree of occupancy by antipsychotic medication compared to the control group. Thus, poor clinical response does not appear to be accounted for by differential blockade, or inadequate occupancy of striatal dopamine D2 receptors by antipsychotic medication.
Collapse
Affiliation(s)
- L S Pilowsky
- Institute of Psychiatry, Genetics Section, De Crespigny Park, London
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
The distribution of the central benzodiazepine receptor specific ligand iodine-123 iomazenil was investigated in seven human adults from whole-body scans, blood samples and urine collected up to 24 h after injection. Using 12 source organs, the MIRD method was applied to calculate the absorbed radiation dose of the radioligand in various organs. The urinary bladder wall (0.15 mGy/MBq), lower large intestinal wall (0.071 mGy/MBq) testes (0.044 mGy/MBq) and upper large intestined wall (0.038 mGy/MBq) received the highest absorbed doses. The average effective dose equivalent of 123I-IBZM for adults was estimated to be 0.033 mSv/MBq.
Collapse
Affiliation(s)
- N P Verhoeff
- Department of Nuclear Medicine, Academic Medical Centre, Amsterdam, The Netherlands
| | | | | | | | | |
Collapse
|
30
|
Verhoeff NP, Bemelman FJ, Wiersinga WM, van Royen EA. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma. Eur J Nucl Med 1993; 20:555-61. [PMID: 8339737 DOI: 10.1007/bf00175168] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
A 28-year-old man with a thyroid stimulating hormone/prolactin (TSH/PRL)-secreting pituitary macroadenoma is discussed in relation to dopamine D2 and somatostatin receptor single-photon emission tomography (SPET). The patient presented with decreased vision in the left eye as a result of a temporal visual field defect and with mild hyperthyroidism. Medical therapy was tried. A test dose of both octreotide and bromocriptine resulted in an acute reduction in serum levels of TSH, alpha-subunits and PRL, whereas there was no response to TRIAC. Somatostatin and dopamine D2 receptors were present on the tumour as visualised by SPET with the ligands indium-111 diethylene triamine penta-acetic acid (DTPA)-octreotide (111In-SMS) and iodine-123 iodobenzamide (123I-IBZM), respectively. Therefore, treatment with octreotide 150 micrograms t.i.d. subcutaneously and bromocriptine 10 mg b.i.d. orally was given for > 12 and > 6 weeks, respectively. Following this treatment the visual defects disappeared, although tumour size, as measured by CT scanning, and serum TSH levels did not decrease. SPET with 111In-SMS and 123I-IBZM after therapy revealed no change or a possible increase in somatostatin receptor binding potential and a possible decrease in dopamine D2 receptor binding potential. The lack of long-term effects of the medical treatment is discussed. It is concluded that a high somatostatin and dopamine D2 receptor binding potential in vivo in a TSH/PRL-producing adenoma does not necessarily predict a successful outcome of medical treatment.
Collapse
Affiliation(s)
- N P Verhoeff
- Department of Nuclear Medicine, Academic Medical Centre, Amsterdam Zuidoost, The Netherlands
| | | | | | | |
Collapse
|
31
|
Abstract
A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. 123I-Iodobenzamide was helpful in evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single-photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205-502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205-502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with 111In-SMS, somatostatin treatment was added to the CV 205-502.
Collapse
Affiliation(s)
- J Assies
- Department of Psychiatry, Academic Medical Centre, Amsterdam, The Netherlands
| | | | | | | |
Collapse
|
32
|
Verhoeff NP, Bekier A, Beer HF, Schubiger PA, Fennema P, van Royen EA. 123I-SCH 23982 is not suitable for dopamine D1 receptor imaging in vivo in the human brain. Nucl Med Commun 1993; 14:137-44. [PMID: 8429993 DOI: 10.1097/00006231-199302000-00012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The tracer 123I-SCH 23982 was tested with regard to its ability to image dopamine D1 receptor in the human brain in vivo with single photon emission computed tomography (SPECT). The tracer did not reach equilibrium with regard to its binding to dopamine D1 receptors, presumably owing to fast metabolism to hydrophilic products and deiodination. It is concluded that 123I-SCH 23982 is not suitable for dopamine D1 receptor imaging with SPECT in the human brain.
Collapse
Affiliation(s)
- N P Verhoeff
- Department of Nuclear Medicine, Academic Medical Centre, Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
33
|
Verhoeff NP, Aldenkamp AP, Overweg J, Van Royen EA, Verbeeten B, Weinstein HC. Memory complaints, memory disorders and focus localization in patients with partial epilepsy. Seizure 1992; 1:149-56. [PMID: 1344759 DOI: 10.1016/1059-1311(92)90017-u] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Our study aimed at analysing effects of epileptic foci on memory function in patients with partial epilepsy. Twenty-eight patients with spontaneous memory complaints and psychometrically established memory disorders were assessed by 21-channel electroencephalography recorded both during cognitive testing and during 99mTc-HMPAO single photon emission computed tomography (SPECT). Computed tomography (CT) was performed on the same day. None of the epilepsy-related factors (seizure type, seizure frequency, type of epilepsy, age at onset of the seizures, type of antiepileptic treatment) could be related directly to severity or type of memory impairment (classified into the categories 'global', 'verbal' and 'non-verbal'). Remarkably, this study found no significant relationship between EEG focus localization and severity of measured memory impairment. Most areas with hypoperfusion on the SPECT were found in the group with global (severe) amnesia, typically with a right frontal localization. Abnormalities on CT were predominantly found in the same group, however, with a right-sided parietal localization. An unanticipated finding was that the majority of temporal CT and SPECT lesions were found in the group with relatively better memory performance.
Collapse
Affiliation(s)
- N P Verhoeff
- Academic Medical Centre, Department of Nuclear Medicine, Amsterdam Zuidoost, The Netherlands
| | | | | | | | | | | |
Collapse
|
34
|
Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340:199-202. [PMID: 1353135 DOI: 10.1016/0140-6736(92)90467-h] [Citation(s) in RCA: 143] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
According to the dopamine hypothesis of schizophrenia, D2 receptor blockade is essential for a drug to have antipsychotic potency, and antipsychotic potency and D2 blockade are linearly related in vitro. To test this assumption in vivo, we have compared clinical response with central D2 dopamine receptor availability measured by 123I-iodobenzamide single photon emission tomography in two groups of schizophrenic patients. 6 patients were on typical antipsychotic drugs and 10 were on the atypical antipsychotic clozapine, including 2 patients from the first group. The patients on typical antipsychotics showed poor therapeutic response despite D2 receptor blockade. Significant clinical improvement occurred in all patients on clozapine, but at a lower level of D2 blockade by the drug. These findings suggest a more complex relation between D2 blockade and clinical efficacy than was previously thought.
Collapse
Affiliation(s)
- L S Pilowsky
- Department of Neuroscience and Psychiatric Genetics, Institute of Psychiatry, Denmark Hill, London, UK
| | | | | | | | | | | |
Collapse
|
35
|
Verhoeff NP. [Cell biology from a medical perspective. X. Signal transduction]. Ned Tijdschr Geneeskd 1992; 136:802. [PMID: 1315426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
36
|
Verhoeff NP, van Royen EA, Speelman JD, Wolters EC, Kuiper MA. [Parkinson disease, a simple diagnosis?]. Ned Tijdschr Geneeskd 1992; 136:757. [PMID: 1560872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
37
|
Speelberg B, Verhoeff NP, van den Berg NJ, Oosthoek CH, van Herwaarden CL, Bruijnzeel PL. Nedocromil sodium inhibits the early and late asthmatic response to exercise. Eur Respir J 1992; 5:430-7. [PMID: 1314192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
A double-blind, crossover study was carried out to investigate the effect of nedocromil sodium on the dual asthmatic response to exercise challenge. Nineteen patients with a late response to bicycle exercise were randomly treated on two study days with 4 mg nedocromil sodium or a matched placebo aerosol, 30 min before commencing exercise. Peak flow was measured before exercise, at intervals up to 60 min after exercise, then hourly for up to 13 h. In 12 of the 19 patients an early reaction to exercise occurred. In 8 of these 12 patients the early reaction could be inhibited by nedocromil sodium (p less than 0.01) although in half of these patients placebo was also shown to be protective. In the case of the late reaction after exercise challenge, 4-13 h after exercise challenge, nine patients were clearly protected by pretreatment with nedocromil sodium (p less than 0.01) when the fall in peak expiratory flow rate was related to the pre-exercise baseline, four patients showed an equal protective effect of placebo and nedocromil sodium, whilst the others were not protected. When the late asthmatic response (fall in peak expiratory flow rate) after exercise challenge was related to control diurnal peak flow values, the number of responses was reduced; the protective effect of nedocromil sodium remained.
Collapse
|
38
|
Speelberg B, Verhoeff NP, van den Berg NJ, Oosthoek CH, van Herwaarden CL, Bruijnzeel PL. Nedocromil sodium inhibits the early and late asthmatic response to exercise. Eur Respir J 1992. [DOI: 10.1183/09031936.93.05040430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A double-blind, crossover study was carried out to investigate the effect of nedocromil sodium on the dual asthmatic response to exercise challenge. Nineteen patients with a late response to bicycle exercise were randomly treated on two study days with 4 mg nedocromil sodium or a matched placebo aerosol, 30 min before commencing exercise. Peak flow was measured before exercise, at intervals up to 60 min after exercise, then hourly for up to 13 h. In 12 of the 19 patients an early reaction to exercise occurred. In 8 of these 12 patients the early reaction could be inhibited by nedocromil sodium (p less than 0.01) although in half of these patients placebo was also shown to be protective. In the case of the late reaction after exercise challenge, 4-13 h after exercise challenge, nine patients were clearly protected by pretreatment with nedocromil sodium (p less than 0.01) when the fall in peak expiratory flow rate was related to the pre-exercise baseline, four patients showed an equal protective effect of placebo and nedocromil sodium, whilst the others were not protected. When the late asthmatic response (fall in peak expiratory flow rate) after exercise challenge was related to control diurnal peak flow values, the number of responses was reduced; the protective effect of nedocromil sodium remained.
Collapse
|
39
|
Verhoeff NP. [Asthma in children; consensus by pediatric pneumonologists about long-term treatment]. Ned Tijdschr Geneeskd 1992; 136:598-9. [PMID: 1552985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
40
|
Verhoeff NP. [The suppressed pill with far-reaching consequences]. Ned Tijdschr Geneeskd 1992; 136:543. [PMID: 1532441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
41
|
Verhoeff NP, Weinstein HC, Aldenkamp AP, Overweg J, Van Royen EA, Verbeeten B. Focus localization in patients with partial epilepsy with 99Tcm-HMPAO SPECT under continuous surface EEG monitoring. Nucl Med Commun 1992; 13:127-36. [PMID: 1557210 DOI: 10.1097/00006231-199203000-00002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Our study was aimed at determining the validity of 99Tcm-HMPAO single photon emission computed tomography (SPECT) in the localization of the epileptogenic focus by correlating this diagnostic method with other auxiliary investigations such as surface EEG and X-ray transmission computed tomography (CT). Twenty-eight patients with partial epilepsy and spontaneous memory complaints were assessed with a 21-channel EEG recorded during psychometric evaluation of the memory complaints and with a 12-channel EEG during 99Tcm-HMPAO SPECT. No significant agreement was observed for total focus localization by the two EEGs, CT or SPECT. The EEGs were highly reproducible. Frontal and temporal pathology on CT resulted in frontal and temporal cold spots on SPECT on the same side in six patients. In addition, SPECT demonstrated frontal, temporal or posterior temporal-inferior parietal cold spots in nine patients without accompanying pathology on CT. It is concluded that CT and SPECT may provide complementary anatomical and functional information, respectively, to the EEG. Furthermore, SPECT may be complementary to CT in visualizing functional deficits without an anatomical correlate. The value of SPECT studies in partial epilepsy may be improved by increasing the resolution of the SPECT system and by simultaneous EEG monitoring.
Collapse
Affiliation(s)
- N P Verhoeff
- Academic Medical Centre, Department of Nuclear Medicine, Amsterdam Zuidoost, The Netherlands
| | | | | | | | | | | |
Collapse
|
42
|
Verhoeff NP, Brücke T, Podreka I, Bobeldijk M, Angelberger P, Van Royen EA. Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with 123I-IBZM using the rotating gamma camera. Nucl Med Commun 1991; 12:687-97. [PMID: 1838141 DOI: 10.1097/00006231-199108000-00004] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Dynamic SPECT was performed in two healthy male volunteers with a single slice brain dedicated camera (Strichman Medical Equipment 810, first study) and a rotating gamma camera (Siemens Dual Rota ZLC37, second study) to obtain information about the optimal imaging time for the dopamine D2 receptor specific ligand 123I-(S)-(-)-2-hydroxy-3-iodo-6-methoxy-N[(1-ethyl-2-pyrrolidinyl) methyl]-benzamide (123I-IBZM). Count rates in the basal ganglia and in several cerebral cortical regions were used to define specific and aspecific binding, respectively. On the basis of the first study, 90-150 min seemed the optimal time for rotating gamma camera 123I-IBZM-SPECT. On the basis of the second study the optimal period was considered to be 60-120 min. It is recommended to apply the same imaging time after injection in a protocol to all patients and volunteers as otherwise a comparison may not be reliable.
Collapse
Affiliation(s)
- N P Verhoeff
- Academic Medical Centre, Department of Nuclear Medicine, Amsterdam, Zuidoost, The Netherlands
| | | | | | | | | | | |
Collapse
|
43
|
Abstract
Neuroreceptor imaging is increasing in nuclear medicine. New generations of radioligands will be developed that will allow us to study neurotransmitter systems not studied before. In data interpretation, however, links will have to be made with the number of counts acquired in the image and the real radioactivity in the brain and then, via the specific activity (and known metabolic characteristics), with the concentration of the ligand. From this point, links will have to be made, via kinetic modelling, with receptor density and, if possible, with receptor affinity, with the final link with brain function at a neurophysiological level. In this article several properties of receptor pharmacology and function are discussed that might help with the interpretation. It is argued that there is a complex relationship between the data, as is apparent in the images recorded and the underlying pharmacology of the receptor. Caution should be exercised, however, when in drawing conclusions about the receptor status and the possible implications on pathophysiology.
Collapse
Affiliation(s)
- N P Verhoeff
- Department of Nuclear Medicine, Academic Medical Centre, Amsterdam Zuidoost, The Netherlands
| |
Collapse
|
44
|
Verhoeff NP, Bobeldijk M, Feenstra MG, Boer GJ, Maas MA, Erdtsieck-Ernste E, de Bruin K, van Royen EA. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain. Int J Rad Appl Instrum B 1991; 18:837-46. [PMID: 1839302 DOI: 10.1016/0883-2897(91)90091-x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
As a promising dopamine D2-receptor imaging agent for single photon emission computerized tomography (SPECT), [123I](S)-(-)-2-hydroxy-3-iodo-6-methoxy-N [(1-ethyl-2-pyrrolidinyl)methyl]benzamide ([123I]IBZM) has recently been synthesized in a modified way along with its precursor, S(-)BZM, and the stereoisomer R(+)BZM. The present study applied this new product to investigate in vitro and in vivo D2-receptor binding in rat brain and in postmortem human brain. In vitro saturation binding curves with [123I]IBZM for rat crude striatal membrane preparations yielded an affinity constant (Kd) of 0.28 nM confirming data in the literature. Displacement curves revealed an order of increasing potency as follows: R(+)BZM less than S(-)sulpiride = less than S(-)BZM less than S(-)IBZM. A similar order was obtained when [3H]spiperone was used as ligand. For human putamen and caudate nucleus membranes slightly higher Kd values (0.49 nM) were obtained. Rank order of displacing potency for the various drugs was similar to that found in the rat preparations. In vivo uptake of [123I]IBZM in rat brain following injection of 50 microCi (12-16 pmol) in the tail vein revealed an increase in the striatum-to-cerebellum ratio from 1.5 at 5 min to 6.9 at 2 h. The olfactory tubercle-to-cerebellum ratio was also raised from 1.6 to 3.3. Other brain regions tested failed to show statistically significant enhancements. Coinjection of 40 nmol S(-)IBZM, 4 mumol S(-)BZM or 200 nmol haloperidol displaced [123I]IBMZ when tested at 90 min. The use of 4 mumol R(+)BZM resulted in minor displacement only, demonstrating that stereospecificity of the displacement was present in vivo and in vitro. Displacements were also observed in substantia nigra and pons-medulla oblongata, but not in hippocampus or frontal and occipital cortex. The data provide the required background needed in order to initiate in vivo binding studies for D2-receptors in basal ganglia of human patients using [123I]IBZM in SPECT analyses.
Collapse
Affiliation(s)
- N P Verhoeff
- Academic Medical Centre, Department of Nuclear Medicine, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Verhoeff NP, Speelberg B, van den Berg NJ, Oosthoek CH, Stijnen T. Real and pseudo late asthmatic reactions after submaximal exercise challenge in patients with bronchial asthma. A new definition for late asthmatic responses after exercise challenge. Chest 1990; 98:1194-9. [PMID: 2225965 DOI: 10.1378/chest.98.5.1194] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The late asthmatic reaction after exercise challenge remains a controversial issue. In this study, 21 patients recorded peak expiratory flow rate (PEFR) on two control days without performing exercise. There was no difference between both control days when PEFR at 1 h was compared with baseline PEFR and when PEFR at 4 to 13 hours was compared with baseline PEFR. After analyzing variation coefficients of baseline PEFR on a control day and exercise day, PEFR was not allowed to differ more than 15.3 percent in the same patient when comparing exercise day and control day for the late fall in PEFR in the study. In 17 of 81 patients, a late asthmatic reaction after exercise challenge was present when PEFR fall was greater than or equal to 20 percent compared with baseline PEFR value. In eight of the 17 patients, a real late asthmatic reaction to exercise challenge was present with a PEFR fall greater than or equal to 20 percent on at least three successive time points and who had a PEFR fall greater than or equal to 20 percent compared with corresponding clocktime on a control day. The late asthmatic reaction to exercise challenge is characterized not as a nonspecific epiphenomenon, but as a fall in PEFR of greater than or equal to 20 percent compared with baseline PEFR value and with corresponding clocktime on a control day on at least three successive time points. Graphic illustration of airway responses following exercises may facilitate the detection of a late asthmatic response.
Collapse
|
46
|
Costa DC, Verhoeff NP, Cullum ID, Ell PJ, Syed GM, Barrett J, Palazidou E, Toone B, Van Royen E, Bobeldijk M. In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans. Eur J Nucl Med 1990; 16:813-6. [PMID: 2209650 DOI: 10.1007/bf00833017] [Citation(s) in RCA: 58] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
3-Iodo-6-methoxybenzamide (123I-IBZM), a new Dopamine D2 receptor ligand, was used in conjunction with SME 810 brain tomography to study six subjects (one normal volunteer, four schizophrenics and one DAT patient). Initial Dynamic SPET was followed by multislice SPET. High-resolution images of the D2 receptor distribution in the basal ganglia were obtained. The specific binding in D2 receptors of the basal ganglia is highest from 2-4 h p.i. Patients on anti-psychotic drugs showed significantly lower specific binding. Dopamine D2 brain receptor availability in man may now be studied with SPET. Continuous data acquisition with single slice tomography is particularly important in the study of this type of radiotracers.
Collapse
Affiliation(s)
- D C Costa
- Institute of Nuclear Medicine, UCMSM, London, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Speelberg B, van den Berg NJ, Oosthoek CH, Verhoeff NP, van den Brink WT. Immediate and late asthmatic responses induced by exercise in patients with reversible airflow limitation. Eur Respir J 1989. [DOI: 10.1183/09031936.93.02050402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The existence and prevalence of late asthmatic responses to exercise in patients is uncertain. We investigated whether the late falls of peak expiratory flow rate (PEFR) after exercise challenge were still significant after comparison with the corresponding clocktime PEFR on a control day. We examined 86 patients with reversible airflow limitation, 79 with asthma and 7 with chronic obstructive pulmonary disease (COPD), all under regular treatment with bronchodilators and/or anti-inflammatory agents. Patients were randomized for a control day and an exercise day and PEFR was recorded hourly. On the exercise day, each patient underwent an 8 minute bicycle ride at 90% of predicted heart-rate. An early and a late asthmatic response to exercise were considered to occur when PEFR decreased by 10% or more on the exercise day compared to the corresponding clocktime PEFR on the control day. Thirty-three patients (38%) had a 10% or greater fall of PEFR at 4 to 13 hours after exercise when PEFR was compared with the corresponding clocktime on a control day. Seven (8%) had an isolated late asthmatic response, and 26 (30%) had a dual asthmatic response. We conclude that true late asthmatic responses develop after exercise in a significant number of patients with well controlled reversible airflow limitation.
Collapse
|
48
|
Speelberg B, van den Berg NJ, Oosthoek CH, Verhoeff NP, van den Brink WT. Immediate and late asthmatic responses induced by exercise in patients with reversible airflow limitation. Eur Respir J 1989; 2:402-8. [PMID: 2759221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The existence and prevalence of late asthmatic responses to exercise in patients is uncertain. We investigated whether the late falls of peak expiratory flow rate (PEFR) after exercise challenge were still significant after comparison with the corresponding clocktime PEFR on a control day. We examined 86 patients with reversible airflow limitation, 79 with asthma and 7 with chronic obstructive pulmonary disease (COPD), all under regular treatment with bronchodilators and/or anti-inflammatory agents. Patients were randomized for a control day and an exercise day and PEFR was recorded hourly. On the exercise day, each patient underwent an 8 minute bicycle ride at 90% of predicted heart-rate. An early and a late asthmatic response to exercise were considered to occur when PEFR decreased by 10% or more on the exercise day compared to the corresponding clocktime PEFR on the control day. Thirty-three patients (38%) had a 10% or greater fall of PEFR at 4 to 13 hours after exercise when PEFR was compared with the corresponding clocktime on a control day. Seven (8%) had an isolated late asthmatic response, and 26 (30%) had a dual asthmatic response. We conclude that true late asthmatic responses develop after exercise in a significant number of patients with well controlled reversible airflow limitation.
Collapse
|